COMPARISON OF CHARACTERISTICS AND TREATMENT OUTCOMES OF TYPE 1 AND TYPE 2 MYOPIC CHOROIDAL NEOVASCULARIZATION AFTER...

Area of Science:

• Ophthalmology
• Retinal Diseases
• Neovascularization

Background:

• Myopic choroidal neovascularization (mCNV) is a leading cause of vision loss in high myopia.
• Understanding the differences between type 1 and type 2 mCNV is crucial for effective treatment.
• Anti-vascular endothelial growth factor (anti-VEGF) therapy is a standard treatment for mCNV.

Purpose of the Study:

• To compare baseline characteristics and one-year treatment outcomes of type 1 and type 2 mCNV after anti-VEGF therapy.
• To identify clinical factors predicting visual outcomes, recurrence, and injection frequency.
• To evaluate the efficacy of anti-VEGF therapy in different mCNV subtypes.

Main Methods:

• Retrospective review of 171 patients with active mCNV treated with anti-VEGF therapy.
• Classification of mCNV into type 1 and type 2 using optical coherence tomography (OCT).
• Comparison of baseline characteristics (BCVA, myopic maculopathy grade, OCT findings) and treatment outcomes.

Main Results:

• Type 1 mCNV presented with worse baseline visual acuity and more severe myopic maculopathy compared to type 2.
• Both types demonstrated significant visual improvement (2.2 lines) after anti-VEGF therapy, with no difference in recurrence or injection numbers.
• Baseline BCVA, myopic maculopathy severity, and subretinal hyperreflective exudation predicted final BCVA; CNV type was not an independent predictor.

Conclusions:

• Both type 1 and type 2 mCNV respond favorably to anti-VEGF therapy, despite initial differences in disease severity.
• Findings support the use of anti-VEGF therapy for type 1 mCNV.
• Individualized management strategies are essential for optimizing visual outcomes in myopic CNV patients.